Analyse van de effectiviteit van 1040 geregistreerde therapeutica op gliomen
Bijdrage Stichting STOPhersentumoren.nl: 142.000,- euro per 29 oktober 2012
Determination of optimal adjuvant drug treatment in patients with malignant glioma by mutational profiling of tumor cells
Bijdrage Stichting STOPhersentumoren.nl: 102.360,- euro per 29 oktober 2012
Rapid and targeted genetic profiling of gliomas for identification of alternative therapeutic options
Bijdrage Stichting STOPhersentumoren.nl: 118.000,- euro per 29 oktober 2012
Improving delivery of therapeutic compounds to invasive glioma
Bijdrage Stichting STOPhersentumoren.nl: 131.625,- euro per 29 oktober 2012
In vitro combination finding of kinase inhibitors in primary glioma cell cultures by means of dynamic kinome profiling
Bijdrage Stichting STOPhersentumoren.nl: 91.900,- euro per 29 oktober 2012